Highest-materiality recent filing
LivaNova Q2 revenue up 10.8% to $390.6M; raises FY2026 guidance
Q2 GAAP diluted EPS $1.93; adjusted diluted EPS $1.26; revenue $390.6M (+10.8% reported, +9.8% constant currency).
LivaNova shareholders approve all 10 proposals at 2026 AGM
All 11 director nominees elected with >99% support, including new members.
LivaNova Q1 revenue $362.3M (+14.3% YoY); raises FY2026 guidance; FDA PMA for aura6000 OSA system
Q1 revenue $362.3M (+14.3% reported, +11.1% CC); GAAP EPS $0.40, adjusted EPS $0.98.
LivaNova Q4 revenue $360.9M (+12.1%); FY25 adj. EPS $3.90; guides FY26 rev. growth 6-7%
Q4 GAAP EPS $0.56; adjusted EPS $0.86. Full-year revenue $1.39B, +10.7% reported.
LivaNova SVP, Chief Legal Officer Michael Hutchinson resigns effective Jan 26, 2026
Michael Hutchinson notified resignation on Jan 12, 2026 as SVP, Chief Legal Officer, and Company Secretary.
LivaNova Q3 revenue $357.8M (+12.5% organic); raises FY2025 EPS guidance to $3.80-$3.90
Third-quarter revenue $357.8M, up 12.5% reported, 11% constant-currency, and 12.5% organic vs prior year.
LivaNova appoints Donald Zurbay to Board and Audit Committee
Donald Zurbay appointed to LivaNova Board and Audit & Compliance Committee effective September 4, 2025.
LivaNova Q2 revenue $352.5M (+10.7%), raises FY25 adjusted EPS guidance to $3.70-$3.80
Revenue $352.5M, +10.7% reported, +10.3% organic; GAAP EPS $0.50, adjusted EPS $1.05.
LivaNova shareholders approve 2.2M share increase in 2022 incentive plan and new director plan
Shareholders approved Second Amended & Restated 2022 Incentive Award Plan, adding 2,200,000 shares for awards.
Italian Ministry seeks €108.8M minimum costs in SNIA case; LivaNova disputes
On May 15, 2025, Italian Ministry served filing to Court of Appeal seeking minimum costs of approximately €108.8M, contrary to Supreme Court's decision that disapproved €157.3M.
Revenue $316.9M, +7.4% reported, +10.4% organic vs Q1 2024.
LivaNova to record ~€333M liability after Italian Supreme Court ruling on SNIA environmental case
Italian Supreme Court rules LivaNova jointly liable for SNIA environmental liabilities of €454M, but excludes €157M in prior payments.
LivaNova Q4 revenue $321.8M (+6.8% organic); FY2025 adjusted EPS guidance $3.65-$3.75
Q4 revenue $321.8M (+6.8% organic YoY); GAAP EPS $1.02, adjusted EPS $0.81.
CMS maintains VNS Therapy for DRE at Level 5 APC for 2025; LivaNova sees no business impact
CMS announced on Nov 1, 2024 it will keep VNS Therapy for drug-resistant epilepsy at Level 5 Neurostimulator APC under the 2025 Medicare Hospital Outpatient PPS.
LivaNova Q3 revenue $318.1M (+11.2% YoY); raises FY2024 guidance
Revenue of $318.1M, up 11.2% reported and constant-currency; ex-ACS wind down, growth 12.3% constant-currency.
LivaNova appoints Susan Podlogar to board and compensation committee
Appointed October 8, 2024 to Board and Compensation and Human Capital Management Committee.
LivaNova CHRO Trui Hebbelinck to depart Sept 30; search for successor
Trui Hebbelinck will leave as Chief Human Resources Officer on Sept 30, 2024, then on garden leave until Sept 30, 2025.
LivaNova Q2 revenue $318.6M (+8.4%), adj. EPS $0.93; raises FY outlook
Q2 revenue $318.6M, up 8.4% reported and 9.6% constant-currency; ex-ACS wind down, constant-currency growth 10.8%.
LivaNova shareholders approve equity plan share pool increases at 2024 AGM
A&R 2022 Plan options/SARs pool increased to 2,950,000 shares from 2,250,000; other awards to 2,000,000 from 1,500,000.
LivaNova Q1 revenue $294.9M (+12% YoY); raises FY2024 guidance; OSPREY study positive
Q1 revenue $294.9M, up 12.0% reported, 12.4% constant-currency YoY; adjusted EPS $0.73 vs GAAP loss $0.78.
LivaNova issues $345M convertible notes, repurchases $230M of existing debt
Issued $345M aggregate principal of 2.50% convertible senior notes due 2029
Priced $300M aggregate principal of 2.50% convertible senior notes due 2029; initial purchasers may buy up to $45M more.
LivaNova announces $300M convertible note offering due 2029, with $45M greenshoe
Proposed $300M convertible senior notes due 2029; initial purchasers granted 13-day option for additional $45M.
LivaNova Q4 revenue $310M (+12.8%), adj. EPS $0.87; full-year $1.15B; new CEO
Q4 revenue $310.1M, up 12.8% reported (11.9% constant currency) vs prior year.
LivaNova appoints Vladimir Makatsaria as CEO effective March 1, 2024; Kozy remains Chair
Vladimir Makatsaria, former J&J MedTech Ethicon head, named CEO and Board member effective March 1, 2024.
LivaNova approves restructuring plan, winds down ACS unit; expects ~$110M impairment in Q4 2023
Board approved restructuring to focus on Cardiopulmonary and Neuromodulation; wind down ACS unit by end of 2024.
LivaNova updates on cyber incident: all manufacturing sites operating at normal levels
All manufacturing sites worldwide substantially operating at normal levels as of Dec 13, 2023.
On Dec 6-7, 2023, LivaNova executives discussed the cybersecurity incident at Mizuho and Wolfe investor meetings.
LivaNova detects cybersecurity incident; business disrupted, impact unknown
Company detected a cybersecurity incident disrupting IT systems; investigation with external experts and law enforcement underway.
LivaNova Q3 revenue $286M (+13.3% YoY); raises full-year guidance
Revenue $286.1M, up 13.3% reported and 12.1% constant currency vs prior year.
LivaNova extends interim CEO Kozy's term; grants $750K RSU award
Board extends interim CEO William A. Kozy's term until earlier of successor CEO start or April 13, 2024.
LivaNova appoints J. Christopher Barry to Board; Andrea Saia to retire Dec 31
J. Christopher Barry appointed to Board and Audit and Compliance Committee, effective Oct 6, 2023.
LivaNova Cardiopulmonary President Marco Dolci to retire Dec 31, 2023
Marco Dolci, President of the Cardiopulmonary Business Unit, announced retirement effective December 31, 2023.
LivaNova Cardiopulmonary President Marco Dolci to retire Dec 31, 2023, receives €860,000
Marco Dolci, President of the Cardiopulmonary business unit, announced retirement effective Dec 31, 2023.
LivaNova Q2 revenue $294M (+16% CC); raises FY guidance; adjusted EPS $0.78
Q2 revenue $293.9M, up 15.6% reported and 16.4% constant currency YoY.
LivaNova shareholders approve amended 2022 incentive plan; increases share pool by 650,000
Shareholders approved Amended & Restated 2022 Incentive Award Plan; options/SARs pool increased from 1,900,000 to 2,250,000 shares; other awards pool from 1,200,000 to 1,500,000 shares.
LivaNova Q1 revenue up 9.7% to $263M, EPS $0.14, raises 2023 guidance; names interim CEO
Revenue $263.4M, +9.7% reported (+12.7% constant currency) vs. prior year.
LivaNova appoints William Kozy interim CEO with $975k salary, $500k RSU grant
William A. Kozy, formerly Chair of Board, appointed interim CEO effective April 14, 2023.
Damien McDonald resigned as CEO effective April 14, 2023; William Kozy appointed interim CEO.
LivaNova completes enrollment of 500th unipolar patient in RECOVER depression trial
Independent committee advised enrollment to continue from 475 to 500 unipolar patients per protocol.
LivaNova Q4 revenue up 6.2% constant currency; adjusted EPS $0.81
Q4 revenue $274.9M (+6.2% constant currency); GAAP EPS $0.03, adjusted EPS $0.81.
LivaNova: RECOVER depression trial enrollment extended to 475 unipolar patients
Independent Statistical Analysis Committee advises to continue enrollment from 450 to 475 unipolar patients.
LivaNova RECOVER depression trial enrollment to continue to 450 patients per DSMB advice
Independent Statistical Analysis Committee advised enrollment continue from 425 to 450 unipolar patients.
LivaNova boosts CFO Alex Shvartsburg's base salary to £430k effective Jan 1, 2023
Base salary increased from £360,000 to £430,000 (approx. 19% increase).
LivaNova announces FDA Warning Letter closed for Munich and Arvada facilities
FDA issued Warning Letter in Dec 2015 over regulatory violations at two facilities.
Independent Statistical Analysis Committee advised continuing enrollment to 425 unipolar patients, up from 400.
Italian Supreme Court referred question to ECJ on whether demerged company can be held liable for post-demerger environmental liabilities from pre-demerger actions.
LivaNova Reports Third-Quarter 2022 Results with Revenue of $252.6M
Revenue of $252.6M decreased 0.2% reported but increased 5.2% on constant-currency basis vs prior year.
LivaNova RECOVER depression trial enrollment continues from 375 to 400 unipolar patients
Independent Statistical Analysis Committee advised continuation of RECOVER trial enrollment from 375 to 400 unipolar patients, per protocol.
LivaNova appoints Brooke Story to Board of Directors effective Sept 15, 2022
Brooke Story appointed to LivaNova Board, brings over 20 years in medtech; currently Worldwide President at BD.
On October 8, 2024, the Board of Directors (the “Board”) of LivaNova PLC (the “Company”) appointed Susan Podlogar to the Board and as a member of the Compensation and Human Capital Management Committee of the Board.
On September 10, 2024, LivaNova PLC (the “Company”) announced that Trui Hebbelinck, the Company’s Chief Human Resources Officer, will leave her position on September 30, 2024 and commence a period of garden leave.
William A. Kozy will step down from his current position as Interim Chief Executive Officer of the Company on March 1, 2024 but will remain the Chair of the Board.
In addition, Mr. Makatsaria was appointed as a member of the Board as of the Effective Date.
the Company’s Board of Directors (the “Board”) appointed Vladimir A. Makatsaria as Chief Executive Officer of the Company, effective as of March 1, 2024
appointed J. Christopher Barry to the Board and as a member of the Audit and Compliance Committee of the Board.
Andrea Saia notified the Company of her decision to retire from the Board, effective December 31, 2023.
On September 21, 2023, LivaNova PLC (the “Company”) reported that Marco Dolci, President of the Company’s Cardiopulmonary Business Unit, announced his intent to retire formally from the Company on December 31, 2023 (the “Retirement Date”).
On September 21, 2023, LivaNova PLC (the “Company”) reported that Marco Dolci, President of the Company’s Cardiopulmonary Business Unit, announced his intent to retire formally from the Company on December 31, 2023 (the “Retirement Date”).
William A. Kozy, Chair of the Company’s Board of Directors (the “Board”), had been appointed interim Chief Executive Officer.
the Company announced that William A. Kozy, Chair of the Board of Directors, has been appointed interim Chief Executive Officer.
the Company announced that Damien McDonald resigned as Chief Executive Officer of the Company and as a member of the Company’s Board of Directors, effective immediately.
Max materiality 0.90 · Median 0.60 · Most common event earnings